Eli Lilly, Tirzepatide and type 2 diabetes

Eli Lilly reports outcomes from Phase III trial of tirzepatide for HFpEF
The trial met both primary endpoints, with tirzepatide showing a 38% decrease in heart failure outcomes compared to placebo.
Tirzepatide Demonstrates Long-Term Weight Reduction and Diabetes Risk Reduction in Obesity and Prediabetes: NEJM
Obesity is a chronic condition and a key risk factor for a range of other health issues, including type 2 diabetes. In a previous analysis of the SURMOUNT-1 trial, tirzepatide pro
Eli Lilly Say Most Tirzepatide Users Remained Diabetes-Free at 176 Weeks
Eli Lilly said new results from a Phase 3 study of its tirzepatide showed weekly injections in adults with pre-diabetes and obesity or overweight resulted in sustained weight loss, with nearly 99% remaining diabetes-free at 176 weeks.
Lilly reports trial results of tirzepatide for treating obesity and pre-diabetes
Spanning 176 weeks of treatment, the Phase III trial evaluated the efficacy and safety of tirzepatide in adults without type 2 diabetes (T2D) who were either obese or overweight with complications such as cardiovascular disease, dyslipidaemia, hypertension, obstructive or sleep apnoea (OSA).
Eli Lilly's weight-loss drug helps nearly 99% of patients remain diabetes-free
Eli Lilly said on Wednesday its weight-loss drug helped nearly 99% of patients remain diabetes-free after three years of weekly injections.
Zepbound Cuts the Risk of Progressing to Diabetes by 94%, Eli Lilly Data Shows
Nearly 99% of people with prediabetes and obesity or overweight who took weekly tirzepatide injections remained diabetes-free for over three years of using the drug, according to new data from the drugmaker Eli Lilly.
Tirzepatide lowered risk of worsening heart failure and CVD death for obese adults
In the international SUMMIT trial, adults with heart failure preserved ejection fraction (HFpEF) and obesity taking ...
Monthly Prescribing Reference2h
Tirzepatide Promising for Patients With HFpEF and Obesity
The Company is seeking approval of tirzepatide for the treatment of HFpEF and obesity and has submitted data to the FDA. Detailed results were announced from a phase 3 clinical trial evaluating ...
Medscape2d
Tirzepatide Reduces Heart Failure Events in HFpEF With Obesity
SUMMT has shown for the first time that a drug can reduce major heart failure clinical outcomes in patients with heart ...
pharmaphorum9h
Tirzepatide gets a big win in obesity-related heart failure
"Obesity contributes to worsening heart failure, and while tirzepatide causes considerable weight loss, research is lacking ...
TCTMD1d
SUMMIT: Tirzepatide a ‘Huge Win’ for HFpEF Patients With Obesity
HF specialists agree these drugs will be key tools in fighting the obesity-related HFpEF epidemic. Hurdles and questions ...
Medpage Today on MSN2d
Tirzepatide Officially Puts GLP-1 Meds on the Map for Obesity-Related Heart Failure
A long-acting GIP/GLP-1 receptor agonist conferred significant clinical benefit for people with obesity and accompanying ...
AHA 2024: GLP-1R agonist associated with better clinical outcomes in heart failure and CKD
Real-world data on GLP-1R agonists’ safety in heart failure and CKD patients was investigated using the TriNetX Research ...
Monthly Prescribing Reference3d
Long-Term Tirzepatide Treatment Reduces Weight and Diabetes Progression Risk
The detailed results were published in The New England Journal of Medicine and were presented at ObesityWeek 2024.
Benzinga.com10h
Eli Lilly's Zepbound/Mounjaro Shows Cardiovascular Benefits In Patients With Obesity-Related Heart Failure
The results from the SUMMIT trial of tirzepatide in obese patients with heart failure ... a nearly 25-point improvement ...
Becker's Hospital Review4d
Mounjaro lowers Type 2 diabetes risk in phase 3 trial: Study
A phase 3 trial found that Eli Lilly's tirzepatide significantly reduced the risk of progression to Type 2 diabetes in prediabetic adults over a three-year period. Nearly 99% of individuals treated ...